Press release
Colorectal Cancer Pipeline Assessment | In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Colorectal Cancer Pipeline
"Colorectal Cancer Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Colorectal Cancer Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Download the sample pages:
https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Colorectal Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights about companies that are developing therapies in the Colorectal Cancer Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer treatment.
• Colorectal Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Colorectal Cancer Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF:
https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Colorectal Cancer Therapeutics Analysis
There are approx. 150+ key companies which are developing therapies for Colorectal Cancer. Currently, Mirati Therapeutics has its Colorectal Cancer drug candidates in the most advanced stage of clinical development.
Colorectal Cancer Therapies covered in the report include:
Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, MacroGenics, Amgen, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Dainippon Pharma, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Merck Sharp & Dohme Corp., AstraZeneca, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Pregen ShenZhen Biotechnology, Puma Biotechnology, G1 Therapeutics, Mologen AG, Sumitomo Dainippon Pharma, Celyad Oncology, Nitto BioPharma, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, AbGenomics B.V, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc. and Others
Colorectal Cancer Therapies covered in the report include:
• Patritumab Deruxtecan (Daiichi Sankyo Company)
• Adagrasib (Mirati Therapeutics)
• Etrumadenant (Arcus Bioscience)
• AL2846 (Advenchen Laboratories)
• Onvansertib (Cardiff Oncology)
And many more
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Colorectal Cancer Current Treatment Patterns
4. Colorectal Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Colorectal Cancer Late Stage Products (Phase-III)
7. Colorectal Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Colorectal Cancer Discontinued Products
13. Colorectal Cancer Product Profiles
14. Colorectal Cancer Key Companies
15. Colorectal Cancer Key Products
16. Dormant and Discontinued Products
17. Colorectal Cancer Unmet Needs
18. Colorectal Cancer Future Perspectives
19. Colorectal Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Colorectal Cancer Pipeline Assessment | In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies here
News-ID: 2706553 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Colorectal
Metastatic Colorectal Cancer Therapeutics Market - Innovation in Motion: Elevate …
Newark, New Castle, USA: The "Metastatic Colorectal Cancer Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Metastatic Colorectal Cancer Therapeutics Market: https://www.growthplusreports.com/report/metastatic-colorectal-cancer-therapeutics-market/8685
This latest report researches the…
Potential Opportunities of Colorectal Cancer Therapeutics Market
The global colorectal cancer therapeutics market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights(TM) titled, "Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and…
Colorectal Cancer Pipeline Therapeutic Review H1 2017
Colorectal Cancer Pipeline Review H1 2017 provides an overview of the Colorectal Cancer (Oncology) pipeline landscape. Colorectal cancer is cancer that starts in the large intestine (Colorectal). There is no single cause of colorectal cancer. Nearly all colorectal cancers begin as noncancerous (benign) polyps, which slowly develop into cancer.
For More on Colorectal Cancer Pipeline Review H1 2017 Report Inquire @
https://goo.gl/1HQ4Fn .
Report Description:
Pharmaceutical guide Colorectal Cancer - Pipeline Review H1…
US Colorectal Cancer Drug Pipeline Analysis
Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die…
Colorectal Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Colorectal Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in…
Colorectal Cancer Treatment Market- Global Outlook 2024
Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which…
